Skip to main content

Advertisement

Advertisement

World

Everything you need to know about Merck's game-changing COVID-19 pill

Everything you need to know about Merck's game-changing COVID-19 pill
File image: Merck & Co's new antiviral medication, molnupiravir. (Merck & Co. via AP, File)

Molnupiravir, an antiviral pill being developed by Merck & Co, has been touted as a potential game-changer in the fight against COVID-19.

The experimental medication was shown to reduce the risk of hospitalisation or death by about half in a late-stage study of adults with mild-to-moderate cases.

The promise of a drug that patients can easily get and take at home has prompted some governments to order supplies even before regulators have decided whether to approve its use. 

WHAT IS MOLNUPIRAVIR?

It is the chemical name for a medicine originally developed to treat influenza that is given orally in a capsule. It inhibits replication of SARS-CoV-2, the coronavirus that causes COVID-19, by a mechanism known as "lethal mutagenesis".

In simple terms, it causes the machinery that reproduces the virus’s genetic material to make mistakes, thereby rendering the copies defective.

The drug was discovered at Emory University in Atlanta, and is being developed by Kenilworth, New Jersey-based Merck and Miami-based Ridgeback Biotherapeutics LP. 

HOW EFFECTIVE IS IT? 

Interim analysis of data from a randomised trial found that it cut the risk of hospitalisation by about 50 per cent, Merck said in an Oct 1 statement.

Of 385 patients who got the drug, 28 or 7.3 per cent were hospitalized, compared with 53 out of 377 (14.1 per cent) who got a placebo. Through day 29, no deaths were reported in patients who received molnupiravir, but eight died in the placebo arm.

The study was relatively small, and further research is required. But results were so encouraging that Merck and Ridgeback, in consultation with independent trial monitors and the US Food and Drug Administration (FDA), halted the trial and began the process of gaining regulatory clearance.

The company said at a conference in September that early research showed molnupiravir can thwart the most common SARS-CoV-2 variants, including delta and gamma.

HOW IS IT DIFFERENT FROM OTHER DRUGS?

Gilead Sciences’s antiviral remdesivir, as well as monoclonal antibodies, are administered via an intravenous infusion. This is usually done in a hospital or a clinic, where infected people risk transmitting the virus to medical staff and other patients.

Molnupiravir’s main advantage is that it’s taken as a pill, enabling patients to be treated at home. It is also likely to be cheaper: A five-day course of molnupiravir will cost about US$700 per patient - a third of the cost of a monoclonal antibody treatment, according to the New York Times.

Safe, well-tolerated, affordable and easy-to-administer antivirals are ideal treatments because they directly counter the virus, limiting its damage to the body and the duration of illness.

Steroids and blood-thinners that have been shown to improve survival in hospitalised patients don’t directly fight the virus; rather they prevent a worsening of COVID-19 symptoms.

HOW WAS IT ADMINISTERED?

Molnupiravir was taken orally every 12 hours for five days by adults with mild-to-moderate COVID-19. Studies are still underway to determine the most efficacious regimen.

A study earlier this year showed molnupiravir had little effect when it was given to patients already hospitalised with severe disease. One study is testing whether it can be used to prevent SARS-CoV-2 from spreading in households in which one or more members have COVID-19.

ARE THERE SIDE EFFECTS?

Interim analysis found no increased incidence of adverse events. Only 1.3 per cent of participants taking molnupiravir quit the therapy due to an adverse event, compared with 3.4 per cent in the placebo group.

Still, molnupiravir will need to be assessed in a much larger group of patients to properly determine its safety. People involved in the trial were instructed to abstain from heterosexual sex or use contraception.

While this is routine practice with some other medicines, such as cancer chemotherapy, it suggests that molnupiravir has the potential to cause birth defects should someone become pregnant. 

WHAT ABOUT THE SUPPLY OF MOLNUPIRAVIR?

Merck expects to make 10 million treatment courses by the end of 2021, with more doses slated for production in 2022.

The drugmaker agreed in June to a US$1.2 billion supply deal with the US government under which it would provide 1.7 million courses of the treatment once the drug gains emergency use authorisation or approval from the FDA.

Merck also has deals with other governments, pending regulatory authorisation. For instance, Australia ordered 300,000 doses. Merck says it will implement a tiered-pricing approach based on World Bank country income criteria to reflect countries’ relative ability to finance their health response to the pandemic.

The drugmaker announced in April voluntary licensing agreements with generic-drug manufacturers in India to accelerate molnupiravir’s availability in more than 100 low- and middle-income countries as soon as the medication gains the necessary approvals.

WILL IT REPLACE THE NEED FOR VACCINES?

No. Vaccination remains the most effective shield against COVID-19.

Still, COVID-19 cases are continuing to occur even in highly vaccinated populations, meaning antiviral therapies will play an important role in limiting the disease’s severity, especially in the elderly and people with weakened immune systems for whom vaccination is less effective.

The best first line of defence against this disease is to not get infected in the first place. Social and public health measures, such as wearing face masks and maintaining a physical distance, are still key to preventing virus transmission and ending COVID-19 epidemics.

BOOKMARK THIS: Our comprehensive coverage of the COVID-19 pandemic and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram

Source: Bloomberg/lk

Advertisement

Also worth reading

Advertisement